LinkZill Completed Pre-A Financing of Several Million Dollars

2021-10-29

LinkZill has completed a Pre-A round of financing led by Zhenfund and followed by Super Gravity Capital. This round of financing will be mainly used for TFT module lab construction, product development and volume release, market investment, and company operation.

 

LinkZill CEO Dr. Feng said that the chip product types have covered mainstream TFT systems, such as amorphous silicon a-Si, oxide IGZO, low-temperature polysilicon LTPS, and organic semiconductor OTFT. The application areas cover high throughput DNA synthesis, active digital microfluidics, high throughput biochemical (including new crown), photo-sensing, etc. The TFT-based active digital microfluidic chip is in the pilot stage, and the TFT-based DNA synthesis and biochemical sensing chip are in the prototype validation stage.

 

Dr. Feng also conveys, China is expected to be the first to upgrade the TFT semiconductor industry and lead the trillion-dollar panel manufacturing industry to complete the conversion from IDM to IDM + Foundry/Fabless model. On the competitive advantage, LinkZill has accumulated three-dimensional technology capability from chip process, simulation, and design to system integration, and mastered cross-field TFT chip IP design, cutting-edge functional materials, product integration, and other core industrialization capabilities. This cross-field capability forms the company’s barrier.

Dr. Kang Kang

Partner & CBio

Dr. Kang received his Ph.D. in Bioinformatics and Systems Biology from the University of Hong Kong in 2018, then became a scientific co-worker of the Leibniz Association (Leibniz-HKI) and a visiting scientist at the Novo Nordisk Foundation Center for Biosustainability (DTU Biosustain) at the Technical University of Denmark. He was a scientist at BGI-Shenzhen and co-founded the synthetic biology research group. He was a senior bioinformatics engineer and brand advisor at WeGene. In 2021, Kang joined Biosysen Limited as a co-founder and served as Chief Informatics Scientist. He is also an advisor and author of the biotech media "Regenesis". He has been dedicated to the R&D and industrialization of OMICs technologies, high-throughput technologies, and synthetic biology for over 10 years. He joined LinkZill in March 2023, responsible for semiconductor life science tools and product planning.